As of 2026-09-28, the EV/EBITDA ratio of Coherus BioSciences Inc (CHRS) is -0.94. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CHRS's latest enterprise value is 143.15 mil USD. CHRS's TTM EBITDA according to its financial statements is -152.66 mil USD. Dividing these 2 quantities gives us the above CHRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.7x - 20.9x | 13.3x |
| Forward P/E multiples | 11.8x - 17.5x | 14.6x |
| Fair Price | (11.52) - (17.08) | (13.58) |
| Upside | -1119.1% - -1611.3% | -1301.7% |
| Date | EV/EBITDA |
| 2026-09-25 | -0.94 |
| 2026-09-24 | -0.98 |
| 2026-09-23 | -1.07 |
| 2026-09-22 | -1.11 |
| 2026-09-21 | -1.18 |
| 2026-09-18 | -1.16 |
| 2026-09-17 | -1.04 |
| 2026-09-16 | -1.03 |
| 2026-09-15 | -1.14 |
| 2026-09-14 | -1.24 |
| 2026-09-11 | -1.14 |
| 2026-09-10 | -1.15 |
| 2026-09-09 | -1.13 |
| 2026-09-08 | -1.18 |
| 2026-09-04 | -1.23 |
| 2026-09-03 | -1.18 |
| 2026-09-02 | -1.23 |
| 2026-09-01 | -1.18 |
| 2026-08-31 | -1.16 |
| 2026-08-28 | -1.22 |
| 2026-08-27 | -1.27 |
| 2026-08-26 | -1.26 |
| 2026-08-25 | -1.18 |
| 2026-08-24 | -1.17 |
| 2026-08-21 | -1.23 |
| 2026-08-20 | -1.13 |
| 2026-08-19 | -1.14 |
| 2026-08-18 | -1.15 |
| 2026-08-17 | -0.96 |
| 2026-08-14 | -1.01 |
| 2026-08-13 | -0.95 |
| 2026-08-12 | -0.98 |
| 2026-08-11 | -1.02 |
| 2026-08-10 | -1.05 |
| 2026-08-07 | -1.08 |
| 2026-08-06 | -1.07 |
| 2026-08-05 | -1.26 |
| 2026-08-04 | -1.29 |
| 2026-08-03 | -1.25 |
| 2026-07-31 | -1.22 |
| 2026-07-30 | -1.28 |
| 2026-07-29 | -1.22 |
| 2026-07-28 | -1.25 |
| 2026-07-27 | -1.27 |
| 2026-07-24 | -1.22 |
| 2026-07-23 | -1.24 |
| 2026-07-22 | -1.24 |
| 2026-07-21 | -1.28 |
| 2026-07-20 | -1.23 |
| 2026-07-17 | -1.21 |